



Diagonal Bio shares progress update on LAMPlify® commercial pilots

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") provides a status update on its completed and ongoing LAMPlify® commercial pilots, including feedback from the participating facilities.

Since the announcement of the first pilot test with LAMPlify in the fall of 2023, Diagonal Bio has launched 13 commercial pilots across 13 facilities in Scandinavia until May 2025, primarily within the equine sector. The standard test period for the LAMPlify commercial pilots is between three to six months. To date, seven commercial pilots have been completed, whereof two LAMPlify platforms have been converted into confirmed instrument sales, and with six commercial pilots still ongoing,

As previously communicated, Diagonal Bio's aims to deliver 30 LAMPlify Systems to end users in 2025, building on the 10 systems delivered in 2024, to accelerate market acceptance and commercial traction. As communicated on 5 May 2025, Diagonal Bio has strengthened its commercialisation strategy with the appointment of Anders Wallseth as Senior Commercial Advisor to accelerate the launch and growth of the LAMPlify system. While important work remains, the Company's ambition to convert 50 percent of the 40 LAMPlify pilots to sales by the end of the year continues, with the efforts from the recently reinforced sales team.

LAMPlify is designed to detect specific equine genetic markers. It can currently identify markers for EHV1, EHV4, EHV5, and EIV with excellent performance, while the development of test kits with additional genetic markers continues. In line with the Company's commercial strategy, throughout 2025, Diagonal Bio will continue to maintain close contact with pilot customers, offering onboarding and technical support, while actively collecting feedback that guides the product development roadmap. This user-driven approach ensures that the LAMPlify system evolves in alignment with real-world needs and expectations. As expected, the close collaboration during the commercial pilots has already revealed further market opportunities, which Diagonal Bio is prioritising as part of its product development roadmap.

"We are pleased with the progress made to date with LAMPlify and the valuable insights we are gathering from our commercial pilots across Scandinavia. The feedback we're receiving from our users is essential as we continue to enhance the platform to better serve the needs of the equine sector and beyond. As we continue to strive towards our ambitious goals, we are confident that the ongoing dialogue with our partners will allow us to deliver a product that meets and exceeds expectations.

We maintain a high-reaching target for 2025, and we are focused on achieving a smooth transition from commercial pilots to full commercial rollout, ensuring the highest standards of quality and customer satisfaction. We look forward to sharing further updates as we progress through the year." - Karin Wehlin, CEO of Diagonal Bio AB (publ)

In connection with this press release, Kalqyl has interviewed Karin Wehlin. Watch it here:

News & Press | Diagonal Bio

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.

For additional information about Diagonal Bio, please contact:

Karin Wehlin, CEO

Phone: +46 70 305 24 88

E-mail: kw@diagonalbio.com